Winter Storm Update – MSK is fully operational. Read more

More Information: Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

HT-144: Human Melanoma Cell Line



HT-144 is a malignant human melanoma cell line that displays aneuploid fibroblastic morphology and grows in adherent tissue culture. This cell line has been reported to be nonpermissive for human cytomegalovirus (HCMV). HT-144 cells form xenograft tumors when injected into immunocompromised mice. These cells contain a mutation in the ATM gene, resulting in the expression of a truncated protein, which causes increased sensitivity to UVB and ionizing radiation compared to other melanoma cell lines. The HT-144 cells also express mutant B-Raf (V600E).


This cell line was established in 1966 from a metastatic site (subcutaneous tissue) in a 29-year-old Caucasian male with malignant melanoma.


  • Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
  • Germaine Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
  • Smith JD (1986) Human cytomegalovirus: demonstration of permissive epithelial cells and nonpermissive fibroblastic cells in a survey of human cell lines. Journal of Virology 60: 583-588 (PubMed ID: 3021992)
  • Ramsay J et al. (1998) Radiosensitive melanoma cell line with mutation of the gene for ataxia telangiectasia. British Journal of Cancer 77: 11-14 (PubMed ID: 9459139)
  • Chen B et al. (2012) BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. PLoS One 7: e42598 (PubMed ID: 22880048)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

Contact Information

  • For licensing requests: Alexandra Buga, MBA, Licensing Associate, Office of Technology Development, MSK, 646-888-1078,
  • For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354,

Stage of Development

Ready to use